

Y. Takada, et al.
U.S.S.N. 10/030,825
Page -5-

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A percutaneously absorbable preparation comprising a salt-form acidic drug and an addition salt compound of a basic substance, wherein the addition salt compound of the basic substance is blended at the range of from 0.5 to 10 fold mole based on the salt-form acidic drug.
2. (Cancelled).
3. (Currently Amended) The percutaneously absorbable preparation according to claim ~~1 or 2~~, wherein the addition salt compounds of the basic substance are salts of ammonium compounds.
4. (Currently Amended) The percutaneously absorbable preparation according to ~~claims 1 to 3~~ claim 1, wherein the percutaneously absorbable preparation is a nonaqueous preparation.
5. (Currently Amended) The percutaneously absorbable preparation according to ~~claim 1~~ claims 1 to 4, wherein the percutaneously absorbable preparation is a matrix-type patch or an ointment.
6. (Currently Amended) The percutaneously absorbable preparation according to any one of claims 1 or 3 to 5, wherein the salt-form acidic drug is an anti-inflammatory drug or a muscular relaxant drug.

Y. Takada, et al.
U.S.S.N. 10/030,825
Page -6-

7. (Original) The percutaneously absorbable preparation according to claim 6, wherein the salt-form acidic drug is an anti-inflammatory drug and the addition salt compound of the basic substance is combined at the range of from 0.5 to 7 fold mole based on the anti-inflammatory drug having salt-form.

8. (Currently Amended) The percutaneously absorbable preparation according to claim 7 ~~claims 1 to 7~~, which is a matrix-type percutaneously absorbable preparation, wherein the anti-inflammatory drug having salt-form and the addition salt compound of the basic substance are contained in an adhesive basis layer.

9. (Original) The matrix-type percutaneously absorbable preparation according to claim 8, wherein the adhesive basis layer is composed of one or more than two of sstylenc-isoprene-styrene block copolymer, polyisobutylene, and acrylic adhesive.

10. (Currently Amended) A percutaneous absorption accelerating composition of the salt-form acidic drug, which contains the addition salt compound of the basic substance, wherein the addition salt compound of the basic substance is blended at the range of from 0.5 to 10 fold mole based on the salt-form acidic drug.

11. (Original) The percutaneous absorption accelerating composition according to claim 10, wherein the addition salt compounds of the basic substance are salts of ammonium compounds.

12. (Original) The percutaneous absorption accelerating composition according to claim 10 or 11, wherein the salt-form acidic drug is an anti-inflammatory drug.